Table 1.
Characteristic of patients classified according to different risk groups and related treatment.
| Diagnosis | n | Age at diagnosis (y) | Age at exam (y) | Time off treatment (y) | Chemotherapy (doses of gonadotoxic chemotherapeutics) | Radiotherapy |
|---|---|---|---|---|---|---|
| HR | 38 | |||||
| HL | 22 | 15.2 ± 2.6 | 21.35 ± 4.4 | 6.03 ± 3.8 | ||
| IIA, IIB | 12 | 3 × MVPP + 3 × B-DOPA Dacarbazine 900 mg/m2 Procarbazine 3000 mg/m2 Nitrogen mustard 36 mg/m2 |
Supradiaphragm 20 Gy | |||
| IIIA | 7 | 3 × MVPP + 3 × B-DOPA | Supradiaphragm 20 Gy Infradiaphragm 15 Gy |
|||
| IIIB | 3 | 4 × MVPP + 4 × B-DOPA Dacarbazine 1200 mg/m2 Procarbazine 4000 mg/m2 Nitrogen mustard 48 mg/m2 |
Supradiaphragm 20 Gy Infradiaphragm 15 Gy |
|||
| BMT | 6 | Busulphane 3 × 16 mg/kg/day Cyclophosphamide 4 × 0.2 g/kg/day |
||||
| CML AML ALL |
2 2 2 |
TBI 12 Gy (1 pt) | ||||
| STS II/III | 3 | CWS 90 Ifosfamide 37.5 g/m2 (Actinomycin D, vincristine) Dacarbazine 2.25 g/m2 Cyclophosphamide 5 g/m2 |
Supradiaphagm 20 Gy (1 pt) Infradiaphragm (49.6 Gy—1 pt, 25 Gy—1 pt) |
|||
| NHL III | 1 | LMB Cyclophosphamide 5.8 g/m2 |
Infradiaphragm 15 Gy | |||
| Wilms tumor | 6 | SIOP (Actinomycin D, vincristine, and epirubicine) |
Infradiaphagm 15 Gy—2 pts 20 Gy—2 pts 25 Gy—1 pt 40 Gy—1 pt |
|||
| III-5 V-1 |
Ifosfamide 36, actinomycin D, and vincristine | |||||
|
| ||||||
| MR | 12 | 8.04 ± 5.5 | 18.36 ± 5.7 | 8.7 ± 4.4 | ||
| AML | 2 | AML—BFM 90 Cytarabine 44.7 g/m2 |
CNS—18 Gy | |||
| STS II | 3 | CWS 96 Ifosfamide 37.5 g/m2—1 pt 42 g/m2—1 pt 48 g/m2—1 pt |
Supradiaphragm 20 Gy | |||
| NBL II | 2 | PACE Cisplatin—2 g/m2 |
— | |||
| NHL II | 5 | BFM 95 Cyclophosphamide 3 g/m2 Ifosfamide 8 g/m2 |
— | |||
|
| ||||||
| LR | 33 | 7.8 ± 5.3 | 17.25 ± 5.0 | 9.0 ± 4.8 | ||
| ALL | 22 | BFM 90 Cyclophosphamide—3.0 g/m2 |
CNS 12 Gy—5 pts CNS 18 Gy—2 pts |
|||
| Germinal tumors | 7 | Without cht—4 TGM 95 (Cisplatin, ifosfamide, and etoposide) |
Unilateral ovariectomy (7) | |||
| Wilms tumor II | 5 | Actinomycin D, vincristine | ||||
HR: high risk group, MR: medium risk group, LR: low risk group, HL: Hodgkin lymphoma, BMT: bone marrow transplantation, CML: chronic myeloid leukemia, AML: acute myeloid leukemia, ALL: acute lymphoblastic leukemia, STS: soft tissue sarcoma, NHL: non-Hodgkin lymphoma, NBL: neuroblastoma, CNS: central nervous system, and TBI: total body irradiation.